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Abstract
There is growing concern about the limitations of rodent models with regard to recapitulation of human
disease pathogenesis. Computational modeling of data from humans and animals sharing similar diseases
provides an opportunity for parallel drug development in human and veterinary medicine. This “reverse
translational” approach needs to be supported by continuing efforts to refine the in silico tools that allow
extrapolation of results between species.
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PERSPECTIVE
Model-Based Reverse Translation Between Veterinary
and Human Medicine: The One Health Initiative
Benjamin Schneider1, Violeta Balbas-Martinez2, Albert E. Jergens3, Inaki F. Troconiz2,
Karin Allenspach3 and Jonathan P. Mochel1*
There is growing concern about the limitations of rodent models with regard to recapitulation of human disease pathogenesis.
Computational modeling of data from humans and animals sharing similar diseases provides an opportunity for parallel drug
development in human and veterinary medicine. This ‘‘reverse translational’’ approach needs to be supported by continuing
efforts to refine the in silico tools that allow extrapolation of results between species.
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IMPROVING THE PREDICTABILITY OF ANIMAL
MODELS USED IN PRECLINICAL RESEARCH
Translational research remains the consensual model to
develop candidate drugs into clinical therapeutics. In the
translational framework, drug pharmacokinetics (PKs) and
pharmacodynamics (PDs) are first characterized in animal
models, and the results of those preclinical studies are then
extrapolated to humans. Currently, out of the few candi-
dates that move forward to the development stage, 35%
attrition in phase II studies are caused by failure to demon-
strate clinical efficacy.1 These high failure rates, combined
with few relevant translational animal models in preclinical
research, highlight the need for alternative approaches
at the early stage of the research and development (R&D)
lifecycle. One such approach is the reverse translational
model.
A well-known application of the reverse translational par-
adigm consists in the prediction of drug side effects and/or
efficacy for individual patients using specific single nucleo-
tide polymorphism information. The scope of reverse trans-
lation is actually broader, as we see it as an opportunity to
synergize the information available from humans and
animals sharing analogous diseases to develop improved
predictions and therapies for both human and veterinary
patients (Figure 1).
The innovative nature of this approach, underpinned by
the “One Health” initiative, is based on the underlying
hypothesis that the use of animal models that spontaneously
develop similar diseases to humans will improve the predict-
ability of preclinical models used for biomedical research
purposes. In return, quantitative PK/PD information gathered
from human clinical studies present an opportunity to stimu-
late veterinary drug development, thus optimizing the utiliza-
tion of existing resources and the application of available
knowledge (i.e., from humans to animals and vice versa).
This contrasts starkly with the common translational practice
of developing genetically engineered animal models of dis-
ease in preclinical research.
In reverse translational pharmacology, computational
modeling of drug PK/PD assists in the selection of promising
therapeutic candidates and the prediction of their optimal
dosing schedules (i.e., dose and frequency) in humans and
animals. This is achieved through extrapolation of disposition
kinetics, efficacy, and safety data from/to spontaneous animal
models of the human disease pathophysiology to/from the
clinic.
One Health and comparative medicine to
support drug R&D
One Health is a cross-disciplinary effort aiming to improve
the assessment, treatment, and prevention of disease in
people and animals.2 An important subfield of One Health is
comparative medicine, which offers the possibility to use
spontaneous animal models with naturally occurring diseases
for drug R&D. These animal models have unique experimen-
tal advantages, especially over the mouse, which may pro-
vide insight into previously intractable diseases. In particular,
many human disorders, including cancer, diabetes mellitus,
chronic enteropathies (e.g., inflammatory bowel diseases
(IBD)), hypertension, and congestive heart failure have well-
studied clinical analogs in dogs (Supplementary Table S1).
Domesticated animals also share several environmental
risk factors with humans, simplifying experimental controls.
In addition, biological relevance of genomic data can be
supported by identifying human-animal genetic homologs,
as is the case in IBD, in which the importance of genetic
susceptibility in disease development has been established
in both species. Below, we highlight three examples of
diseases in which reverse translational modeling have been
used to support pharmaceutical research.
Cancer research
About 6 million dogs are diagnosed with cancer each year,
and >50% of dogs of 10 years or more will develop can-
cers, such as lymphoma, osteosarcoma, and melanoma.3
Although murine models have been extremely useful for
studying the biology of cancer development, mice usually
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do not adequately represent many of the features constitutive
of human cancers, including genomic instability and tumor
heterogeneity.4 In dogs, cancers develop naturally within a
syngeneic host and tumor microenvironment, and in the con-
text of an intact immunity. Dogs and human cancers share
similar features, such as background genetics, histological
appearance, therapeutic response, and acquired resistance.4
One good example of the use of canine models to support
cancer therapy pertains to the development of the inflamma-
tory cytokine interleukin (IL)-12 as a potential treatment for
malignant melanoma. The use of cytokines to enhance antitu-
mor immunity has been recognized as an important immuno-
modulatory approach in cancer management. Yet, historically,
the high risk for systemic toxicity presented by IL-12 dosing
has prevented development of this cytokine into a therapeutic.
A strong genetic similarity exists between canine and human
IL-12 (i.e., 84% homology for the ligand and 68% homology
for the receptor), whereas dogs develop spontaneous malig-
nant melanoma with similar biology to human tumors. These
analogies provided impetus for the characterization of IL-12
PK/PD, efficacy, and toxicity in canine clinical trials.5 Results
from the dog study showed that high levels of IL-12 could be
safely administered subcutaneously to patients with malignant
melanoma, while maintaining both systemic immunological
and clinical activity. This was demonstrated by measuring
serum IL-12 and other representative biomarkers (e.g., IL-10)
over time, and establishing PK/PD models of IL-12. These
findings in dogs were key to guide the sponsor’s decision to
move forward with a phase I clinical trial in humans. In turn,
preliminary studies focusing on IL-12 gene electrotransfer in
dog patients with melanoma have shown promising results for
the treatment of spontaneous canine tumors.6
Inflammatory bowel disease
IBD is a highly prevalent disorder in both humans and dogs.
Importantly, dogs with IBD exhibit similar clinical symptoms,
show involvement of the same cells, inflammatory genes and
molecular pathways, and have a time course of disease
progression similar to humans. In fact, a copious amount of
literature has established that human and canine IBD have
common clinical and molecular features, such that clinical
trials in dogs with IBD are particularly relevant to study the
efficacy and safety of candidate drugs intended for use in
humans.7 In a recent collaboration between the Iowa State
University and the University of Navarra, IBD was modeled
using a network systems approach based on Boolean
Figure 1 Translational vs. reverse translational sciences. Reverse translational sciences is a bidirectional approach in which clinical
findings from patients are used to design early studies in relevant animal models of (spontaneous) disease. The information generated
in animal studies will later be used to predict the efficacy and safety of future therapeutics in human clinical trials.
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equations.8 The model was used to simulate the effect of a
noncompetitive antagonist of the purinergic receptor P2X7
and guide dose selection for an upcoming clinical study in
IBD in dogs. The model used inflammatory biomarkers IL-1b
and IL-18 as well as the tissue damage biomarkers matrix
metalloproteinases as surrogate end points of efficacy.
Assuming that matrix metalloproteinases levels are associ-
ated with clinical disease activity, results from the simulations
showed that the selected dose of the drug candidate should
antagonize at least 75% of the target receptor. These findings
will now inform the design of a proof-of-concept study in IBD
dogs prior to clinical development in humans.
Congestive heart failure
Another therapeutic indication in which modeling efforts
have been made to better characterize the effects of drugs
in naturally occurring animal models of human disease is
congestive heart failure (CHF). In humans and dogs, CHF
is often synergistic with renin angiotensin aldosterone sys-
tem (RAAS) overactivation. This is due to the excessive
release of renin from the juxtaglomerular apparatus, a well-
described compensatory mechanism to the reduced cardiac
output observed in symptomatic stages of CHF. Although
there is no mathematical description of the PK/PD of
angiotensin-converting enzyme (ACE) inhibitors in sponta-
neous cases of canine CHF, the kinetics and effects of
benazeprilat have been characterized in a low-salt diet
model of RAAS activation.9 Similar to humans, ACE inhibi-
tors are commonly dosed in the morning in dogs. However,
using a nonlinear mixed-effect model to describe the
dynamics of RAAS biomarkers in dogs, Mochel et al.9 have
shown that the timing of food intake exerts a synchronizing
effect on the RAAS, such that dosing with ACE inhibitors
should be adjusted according to the time of food intake.
Using a mechanism-based PK/PD model, the authors
further established that ACE activity alone was not a pre-
dictive marker of RAAS activity in dogs because, as
reported in humans, benazeprilat exerts a moderate effect
on angiotensin II and aldosterone, despite a complete and
long-lasting inhibition of ACE.
Opening the “Black Box” of complex biological
networks
The reductionist approach to biomedical research has been
successful in identifying key mechanisms contributing to
disease modulation. However, it has become increasingly
apparent that a more integrated approach is required to
characterize the pathophysiology of complex biological sys-
tems. This was nicely illustrated with the IBD example
above for which a systems pharmacology model comprised
of 43 nodes and 298 interactions was developed by com-
bining human and animal data on a large number of cyto-
kines, immune cells, and proteins to predict the therapeutic
efficacy of prospective candidate drugs. As high-throughput
sequencing and metabolomics techniques continue to
improve, this mechanistic model could be expanded further
to decipher the mechanisms by which diet and genetic
backgrounds impact disease susceptibility.10
CONCLUSION
Reverse translational pharmacology is an expanding field of
research with the promise to improve existing preclinical
models for better characterizing the efficacy and safety of
candidate drugs and, ultimately, selecting the most promising
therapeutics intended for use in humans. In return, from the
perspective of developing veterinary pharmaceuticals for
spontaneous diseases in animals, reverse translational phar-
macology also presents an opportunity to leverage informa-
tion from PK and PD studies in humans for the benefit of
veterinary medicine. The success of the reverse translational
paradigm relies on more systematic interdisciplinary research
and cross talks among physicians, veterinarians, and quanti-
tative scientists. To achieve this, the Comparative Oncology
Program of the National Cancer Institute has established a
multicenter collaborative network of 22 veterinary academic
partners known as the Comparative Oncology Trials Consor-
tium. The mission of the Comparative Oncology Trials Con-
sortium is to answer biological questions geared to inform the
development path of chemotherapeutics for future use in
human patients with cancer. Additional initiatives from the
National Institute of Health include several multimillion-dollar
funding opportunities to foster collaborative programs for
multidisciplinary teams (e.g., PAR-17–340 and RFA-CA-17-
002). Active participation of industrial partners is also key to
the success of reverse translational research. This was
exemplified by the 5-year Cooperative Research and Devel-
opment Agreement between the US Food and Drug Adminis-
tration Center of Veterinary Medicine and Certara (www.
certara.com) aiming to deliver physiologically based PK dog
models and assesses the impact of polymorphic variations
on interspecies extrapolation. Regulatory incentives to
develop parallel (veterinary and human) drug development
programs could present an opportunity to encourage such
collaborations in the future.
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